首页|钠-葡萄糖共转运蛋白2抑制剂治疗非糖尿病疾病的系统综述

钠-葡萄糖共转运蛋白2抑制剂治疗非糖尿病疾病的系统综述

扫码查看
钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂作为一种新型降糖药,为糖尿病患者带来新的获益.近年来研究发现,SGLT-2抑制剂在心血管疾病、肾脏病、减重、非酒精性脂肪性肝病等非糖尿病疾病中有显著的治疗作用.现就SGLT-2抑制剂在非糖尿病疾病中的作用机制、安全性及临床应用要点等方面的研究做一综述,为SGLT-2抑制剂在非糖尿病疾病的治疗提供更多的临床应用依据.
Systematic Review of Sodium-glucose Cotransporter 2 Inhibitors in the Treatment of Non-diabetic Diseases
Sodium-glucose cotransporter 2(SGLT-2)inhibitor,as a new type of hypoglycemic agent,brings new benefits to diabetic patients.Recent studies have found that SGLT-2 inhibitors have significant therapeutic effects on non-diabetic diseases such as cardiovascular disease,kidney disease,weight loss,and non-alcoholic fatty liver disease.Here is to make a review on the mechanism,safety and clinical application of SGLT-2 inhibitors in non-diabetic diseases,so as to provide more clinical application basis for SGLT-2 inhibitors in the treatment of non-diabetic diseases.

SGLT-2 inhibitorsNon-diabetic diseaseCardiovascular diseaseKidney diseaseLose weightNon-alcoholic fatty liver disease

韦海燕、郭予洁

展开 >

柳州市人民医院老年病科,广西 柳州 545000

SGLT-2抑制剂 非糖尿病疾病 心血管疾病 肾脏病 减重 非酒精性脂肪性肝病

柳州市科技计划

2021CBC0106

2024

医学信息
国家卫生部信息化管理领导小组 中国电子学会中国医药信息学分会 陕西文博生物信息工程研究所

医学信息

影响因子:0.161
ISSN:1006-1959
年,卷(期):2024.37(16)